SlideShare a Scribd company logo
1 of 20
Prevention of Postoperative
Atrial Fibrillation
April 7, 2016
NYU Adult-Gerontology Acute Care III
Jennifer Stieber
Setting: CV/Thoracic Surgery Post-op unit
HPI
This is Martha, 64 y.o. female with history of
CAD s/p stents in Oct 2016, HLD, HTN, TR,
sleep apnea, insomnia, anxiety, overactive
bladder, GERD, lap band removed due to
perforation, who presented with cough and
fatigue for several weeks, and was treated for
RUL pneumonia and abscess as an outpatient
with azithromcycin, followed by prednisone and
levaquin without improvement. She was referred
to thoracic surgery and was admitted for a R
thoracotomy and R upper lobe resection.
Home meds:
lipitor 20mg po daily
cymbalta 60mg daily
ASA 81 mg daily
clopidogrel 75 mg daily
Social:
No EtOH
No tobacco
Retired teacher
Lives with husband in Brooklyn
NKDA
Hospital course:
3/9- admitted, IV tygacil started. 3/10 echo done. 3/12 - R upper lobectomy
without complications, chest tube placed 3/13 - transferred to POU, hypotension
and low UO treated with IVF, albumin, lasix, neo. 3/14 - afib with RVR to 120s,
7.5mg metoprolol, amio load and drip. Neo for BP support. 3/15 - NSR, neo off,
transitioned to PO amio, heparin gtt started. lung tissue culture shows moderate
Strep intermedius, sputum with H. influenzae 3/16 PICC placed for long term IV
abx 3/17 - doing well with PT heparin drip continued 3/18 - doing well with PT.
Heparin drip off. 3/19 - chest tube remains with +airleak
Physical Exam
General appearance: Alert female sitting up in
chair, no acute distress
Neck: supple, midline
Lungs: clear to auscultation bilaterally, R CT to
water seal. No crepitus.
Heart: S1, S2, regular rate and rhythm
Abdomen: soft, nontender, nondistended
Extremities: +1 edema to bilateral lower legs,
warm and well perfused throughout
Pulses: +2 radial pulses, +2 pedal pulses
Incision: R thoracotomy incision clean dry intact.
No redness, no swelling, no drainage
Neurologic: AOx3, responds to questions
appropriately, movement and sensation intact
throughout.
Vital Signs:
110/54
HR 62
97% on room air
RR 15
97F
Labs:
WBC 11
Hgb 8.9
Hct 27.4
Plt 293
Na 130
K 4.2
Cl 99
CO2 25
BUN 26
Cr 0.8
Glu 101
Ca 7.4
Alb 2
Imaging
Chest CT 03/07/16
Impression:
Moderate to large right
upper lobe infiltrate with
atelectasis containing fluid
collection with air-fluid
levels, worrisome for
abscess.
Imaging/tests
EKG from 3/14
Ventricular Rate: 105 BPM
Atrial Rate: 113 BPM
QRS Duration: 146 ms
Q-T Interval: 358 ms
QTC Calculation(Bezet): 473 ms
R Axis: -54 degrees
T Axis: 105 degrees
Atrial fibrillation with rapid ventricular response
Non-specific intra-ventricular conduction delay
Nonspecific ST and T wave abnormality
Abnormal ECG
Echo TTE 03/10/16
CONCLUSION:
--There is no left atrial dilatation (LA volume
index 24 ml/m²).
--There is paradoxical septal motion. Other
LV walls are normal.
--LV ejection fraction is normal.
--The right ventricle has normal wall motion.
--The right atrial pressure is normal (0 - 5 mm
Hg). There is no pulmonary hypertension.
--There is no pericardial effusion. Prominent
epicardial fat pad.
--No prior study available for comparison.
3/19/16 CXR:
Findings / Impression:
Status post right thoracotomy for partial right
lung resection. Right pleural chest tube
remains. Previously described small right
apical pneumothorax is no longer discernible.
Cardiomediastinal silhouette is unremarkable
for portable technique.
Assessment
This is a 64 year old female with
history significant for CAD s/p
stents, HLD, HTN, TR, who is
post op day #8 s/p R upper lobe
resection of a cavitary abscess
and pneumonia, course
complicated by afib with RVR
now on PO amio, rehabilitating
well in post op unit.
Plan
Pulm - s/p RUL lobectomy for cavitary
mass
- ipratropium neb q4h
- albuterol 2.5 mg q4h
- Chest PT
- incentive spirometry
- OOB as tolerated
- DC chest tube when air leak
resolved
Cardiac- CAD s/p stents, HTN, HLD
- ASA 81 mg daily
- clopidogrel 75 mg daily
- lipitor 20mg po daily
- amiodarone 400mg PO twice daily
- metoprolol 12.5 mg po q12h
- heart healthy diet
- Maintain K>4 and mag>2
- Daily weights
- Trend I/Os
Neuro - post op pain, anxiety, insomnia
- cymbalta 60mg daily
- 5 mg oxycodone q4 hrs PRN for
pain
Plan
Renal - hyponatremia
- Trend BUN/Cr
- asymptomatic
hyponatremia, today
Na=130, continue 1000ml
daily fluid restriction
ID - cavitary lung abscess
-s/p PICC
- tygacil 50 mg IV q12 hrs
- trend WBC
- monitor temps q4h
- monitor cough and sputum
Prophylaxis:
- heparin subq 5000 units BID
- protonix 40mg daily
- Colace/senna
Surgery
atrial fibrillation
Prolongs hospital stay Thromboembolic events
Worse long term prognosis
$10,000 per
patient
(Onk and Erkut, 2015)
PICO
In post-operative cardiothoracic patients,
is amiodarone, compared to other
therapies, more effective at preventing
atrial fibrillation?
● Increased atrial
pressure/atrial
enlargement
● Metabolic and electrolyte
changes
● Myocardial ischemia
● Aging
● Oxidative stress
● Hypertension
● Low EF
● ICU stress
● Pericardial inflammation
● Catecholamine release
● Systemic inflammation
● Local inflammation
Hypothesized triggers of atrial fibrillation:
● OR, interaction of all of these factors
Study 1:
“Is the Preoperative
Administration of Amiodarone
or Metoprolol More Effective in
Reducing Atrial Fibrillation?”
2015
Authors: Onk and Erkut
Journal: Medicine
Type of study: randomized control trial, nonblind
n= 251
Methods: 251 pre-CABG were randomly divided into 2
groups: one given metoprolol 50 mg/day vs amio
200 mg/daydaily 1 week prior to surgery and
during post-op period. Followed up 1 month
Results: AF in 14 amio patients, AF in 16 metoprolol
patients (p=0.612). No significant differences in
length of stay, cost of stay (p=0.741)
Weaknesses: only 48 hrs of tele, then daily EKG after
that. anyone with extensive cardiac history was
excluded- valve dysfunction, HF class III, prior
stents, etc
Strengths: no bradycardia, no heart block, no
discontinuation of therapy due to side effects, no
statistical differences in vessel disease, the
amount of bleeding, inotropic support, duration
to extubation, use of IABP, renal dysfunction
Study 2:
“Role of Atorvastatin
Administration in Protection
Against Postoperative Atrial
Fibrillation Following
Conventional CABG”
2011
Authors: Sun et al.
Journal: International Heart
Journal
Type of study: randomized control trial, single blind
placebo
n= 100
Methods: 49 given atorvastatin 20 mg daily 7 days
before surgery, 51 given placebo. The primary
endpt was occurrence of AF, CRP was measured
pre-op and q24 hrs post op until discharge.
Results: Atorvastatin significantly reduced the
incidence of postop AF (18% vs 41%, p=0.017).
and postop peak CRP level (129 vs 149 p<0.0001.)
Significantly better postop afib-free survival in
statin group. Pre op atorvastatin tx was
independently associated with significant
reduction in post op AF (p=0.007).
Weaknesses: no race mentioned, hospital stay was 13-
14 days
Strengths: ECG for 7 days post op, all operations
performed by 1 surgeon. no previous statin use,
no hx afib. No sig differences in vessel disease, hx
of infarct, HLD, HTN between groups. No GI or
Study 3:
“Dexamethasone for the
prevention of postoperative
atrial fibrillation” (DECS trial)
2015
Authors: Osch et al.
Journal: International Journal of
Cardiology
Type of study: randomized control trial, double blind
n= 4494 cardiac surgery pts
Methods: 2239 received single dose dex, 2255 placebo.
Patients were randomized to receive an intravenous
injection dexamethasone (1 mg/kg, with a maximum
total dose of 100 mg) or placebo, immediately after
the induction of anesthesia, but before the initiation
of CPB
Results: The incidence of any AF in the main study of 4494
patients was 33.1% in the dexamethasone and 35.2% in
the placebo group (RR 0.94, 95% CI: 0.87–1.02,
p=0.14). In the substudy of 1565 patients (more in
depth analysis), the incidence of new onset AF was
33.0% vs. 35.5% (RR 0.93, 95% CI: 0.81–1.07, p=0.31),
respectively.
Weaknesses: Visceral abdominal obesity is important
modulator of postoperative inflammation. Did not
collect baseline waist circumference as a possible
modulator of the effect of dexamethasone on AF
Strengths: high rate of follow up (loss of 4 in exp, loss of 8
in control group). The analysis of the ECGs, patient
Study 4:
“Ranolazine Enhances the Antiarrhythmic
Activity of Amiodarone by Accelerating
Conversion of New-Onset Atrial Fibrillation
After Cardiac Surgery”
2014
Authors: Simopoulos et al.
Journal: Coronary Heart Disease
Study year: 2014
Type of study: prospective randomized control trial,
single blind
n=41, 20 exp, 21 control
Methods: enrolled consecutive patients who
developed POAF after elective on-pump CABG,
randomized to receive either ranolazine 375 mg
twice daily orally plus intravenous amiodarone
(active group) or intravenous amiodarone alone
(control group).
Results: Time to conversion, hrs 19.9 vs 37.2 (p<.001)
Weaknesses: small sample size, but stat sig. Could be
drug independent spontaneous conversion.
Strengths: same surgeons and anesthesiologists for
each procedure. None of the patients who
received ranolazine in addition to amiodarone
showed any hemodynamic deterioration or
proarrhythmic effects during the entire treatment
References:
1. Onk and Erkut. (2015). Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in
Reducing Atrial Fibrillation. Medicine. 94(41)
2. Sun Y1, Ji Q, Mei Y, Wang X, Feng J, Cai J, Chi L.(2011). Role of Atorvastatin Administration in Protection Against
Postoperative Atrial Fibrillation Following Conventional CABG. International Heart Journal 52(1):7-11.
3. Osch, Dieleman, van Dijk, Jacob, Luin, Doevendans, Nathoe. (2015). Dexamethasone for the prevention of
postoperative atrial fibrillation. International Journal of Cardiology 182:431-437.
4. Simopoulos, V, Tagarakis G, Daskalopoulou S, Chryssagis, K, Skoularingis, I, Molyvdas, P, Tisilimingas, N,
Aidonidis, I. (2014). Ranolazine Enhances the Antiarrhythmic Activity of Amiodarone by Accelerating Conversion
of New-Onset Atrial Fibrillation After Cardiac Surgery. Coronary Heart Disease 65(4) 294-297.

More Related Content

What's hot

Atrial Fibrillation (Brigham and Women's)
Atrial Fibrillation (Brigham and Women's)Atrial Fibrillation (Brigham and Women's)
Atrial Fibrillation (Brigham and Women's)Ameer H. Ahmed
 
atrial fibrillation
atrial fibrillation atrial fibrillation
atrial fibrillation auriom
 
ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016Ravikanth Moka
 
Case Report: Atrial Fibrillation with Rapid Ventricular Response
Case Report: Atrial Fibrillation with Rapid Ventricular ResponseCase Report: Atrial Fibrillation with Rapid Ventricular Response
Case Report: Atrial Fibrillation with Rapid Ventricular ResponseJohn R. Martinelli, MD, OD
 
atrial fibrillation- management
atrial fibrillation- management atrial fibrillation- management
atrial fibrillation- management amish117
 
Atrial fibrilation
Atrial fibrilationAtrial fibrilation
Atrial fibrilationSujit Sahu
 
Atrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspectiveAtrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspectiveSrikanthK120
 
Atrial fibrillation management
Atrial fibrillation managementAtrial fibrillation management
Atrial fibrillation managementBasem Enany
 
Atrial fibrillation ksaus hs 2019
Atrial fibrillation ksaus hs 2019Atrial fibrillation ksaus hs 2019
Atrial fibrillation ksaus hs 2019hospital
 
Artrial fibrillation classification & management guideline
Artrial fibrillation classification & management guidelineArtrial fibrillation classification & management guideline
Artrial fibrillation classification & management guidelineDr. Rohan Sonawane
 
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and AblationDabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and Ablationlarriva
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation Syed Raza
 
Atrial Fibrillation Epidemiology, pathogenesis, diagnosis and treatment
Atrial Fibrillation  Epidemiology, pathogenesis, diagnosis and treatmentAtrial Fibrillation  Epidemiology, pathogenesis, diagnosis and treatment
Atrial Fibrillation Epidemiology, pathogenesis, diagnosis and treatmentSuharti Wairagya
 

What's hot (20)

Atrial Fibrillation (Brigham and Women's)
Atrial Fibrillation (Brigham and Women's)Atrial Fibrillation (Brigham and Women's)
Atrial Fibrillation (Brigham and Women's)
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
atrial fibrillation
atrial fibrillation atrial fibrillation
atrial fibrillation
 
ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Case Report: Atrial Fibrillation with Rapid Ventricular Response
Case Report: Atrial Fibrillation with Rapid Ventricular ResponseCase Report: Atrial Fibrillation with Rapid Ventricular Response
Case Report: Atrial Fibrillation with Rapid Ventricular Response
 
atrial fibrillation- management
atrial fibrillation- management atrial fibrillation- management
atrial fibrillation- management
 
Atrial fibrilation
Atrial fibrilationAtrial fibrilation
Atrial fibrilation
 
Atrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspectiveAtrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspective
 
Atrial fibrillation management
Atrial fibrillation managementAtrial fibrillation management
Atrial fibrillation management
 
Af
AfAf
Af
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Atrial fibrillation ksaus hs 2019
Atrial fibrillation ksaus hs 2019Atrial fibrillation ksaus hs 2019
Atrial fibrillation ksaus hs 2019
 
Artrial fibrillation classification & management guideline
Artrial fibrillation classification & management guidelineArtrial fibrillation classification & management guideline
Artrial fibrillation classification & management guideline
 
A fib lecture
A fib lectureA fib lecture
A fib lecture
 
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and AblationDabigatran for Atrial Fibrillation: Cardioversion and Ablation
Dabigatran for Atrial Fibrillation: Cardioversion and Ablation
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
 
A fib
A fibA fib
A fib
 
Atrial Fibrillation 2016
Atrial Fibrillation 2016Atrial Fibrillation 2016
Atrial Fibrillation 2016
 
Atrial Fibrillation Epidemiology, pathogenesis, diagnosis and treatment
Atrial Fibrillation  Epidemiology, pathogenesis, diagnosis and treatmentAtrial Fibrillation  Epidemiology, pathogenesis, diagnosis and treatment
Atrial Fibrillation Epidemiology, pathogenesis, diagnosis and treatment
 

Viewers also liked

Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation SMSRAZA
 
Atrial Fibrillation Case Study
Atrial Fibrillation Case StudyAtrial Fibrillation Case Study
Atrial Fibrillation Case StudyBetty Kui
 
Cia #4 atrial fibrillation
Cia #4   atrial fibrillationCia #4   atrial fibrillation
Cia #4 atrial fibrillationsm765012
 
2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelinespurplevivid
 
FAHMI RAIS CV 2015
FAHMI RAIS CV 2015FAHMI RAIS CV 2015
FAHMI RAIS CV 2015Fahmi Rais
 
Antithrombotic therapy after pci in atrial fibrillation 2016
Antithrombotic therapy after pci in atrial fibrillation 2016Antithrombotic therapy after pci in atrial fibrillation 2016
Antithrombotic therapy after pci in atrial fibrillation 2016University of Messina (Italy)
 
Fibrilacion auricular
Fibrilacion auricularFibrilacion auricular
Fibrilacion auricularJJ CV
 
Persistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventationPersistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventationsalah_atta
 
Paraneoplastic syndromes - CNS manifestations
Paraneoplastic syndromes - CNS manifestationsParaneoplastic syndromes - CNS manifestations
Paraneoplastic syndromes - CNS manifestationsDeepak Chinagi
 
Chapter 11 - Putting It All Together
Chapter 11 - Putting It All TogetherChapter 11 - Putting It All Together
Chapter 11 - Putting It All Togetherryanhall911
 
STEMI, N-STEMI, and Everything else
STEMI, N-STEMI, and Everything elseSTEMI, N-STEMI, and Everything else
STEMI, N-STEMI, and Everything elseRobert Cole
 
Management of atrial fibrillation in critically ill patients
Management of atrial fibrillation in critically ill patientsManagement of atrial fibrillation in critically ill patients
Management of atrial fibrillation in critically ill patientsChamika Huruggamuwa
 
Evaluation and Initial Treatment of Supraventricular Tachycardia
Evaluation and Initial Treatment of Supraventricular TachycardiaEvaluation and Initial Treatment of Supraventricular Tachycardia
Evaluation and Initial Treatment of Supraventricular TachycardiaSun Yai-Cheng
 
American Heart Association Emergency Medicine Update Cardiology- EM Residency...
American Heart Association Emergency Medicine Update Cardiology- EM Residency...American Heart Association Emergency Medicine Update Cardiology- EM Residency...
American Heart Association Emergency Medicine Update Cardiology- EM Residency...Troy Pennington
 
Atrial fibrillation -latest
Atrial fibrillation -latestAtrial fibrillation -latest
Atrial fibrillation -latestPraveen Nagula
 
ST elevation
ST elevationST elevation
ST elevationtbf413
 

Viewers also liked (20)

Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
 
Atrial Fibrillation Case Study
Atrial Fibrillation Case StudyAtrial Fibrillation Case Study
Atrial Fibrillation Case Study
 
V klass
V klassV klass
V klass
 
Cia #4 atrial fibrillation
Cia #4   atrial fibrillationCia #4   atrial fibrillation
Cia #4 atrial fibrillation
 
2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines
 
FAHMI RAIS CV 2015
FAHMI RAIS CV 2015FAHMI RAIS CV 2015
FAHMI RAIS CV 2015
 
Guillermo aldama manejo antiagregación en fa anticoagulada v1
Guillermo aldama   manejo antiagregación en fa anticoagulada v1Guillermo aldama   manejo antiagregación en fa anticoagulada v1
Guillermo aldama manejo antiagregación en fa anticoagulada v1
 
Antithrombotic therapy after pci in atrial fibrillation 2016
Antithrombotic therapy after pci in atrial fibrillation 2016Antithrombotic therapy after pci in atrial fibrillation 2016
Antithrombotic therapy after pci in atrial fibrillation 2016
 
Fibrilacion auricular
Fibrilacion auricularFibrilacion auricular
Fibrilacion auricular
 
Persistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventationPersistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventation
 
Paraneoplastic syndromes - CNS manifestations
Paraneoplastic syndromes - CNS manifestationsParaneoplastic syndromes - CNS manifestations
Paraneoplastic syndromes - CNS manifestations
 
Chapter 11 - Putting It All Together
Chapter 11 - Putting It All TogetherChapter 11 - Putting It All Together
Chapter 11 - Putting It All Together
 
STEMI, N-STEMI, and Everything else
STEMI, N-STEMI, and Everything elseSTEMI, N-STEMI, and Everything else
STEMI, N-STEMI, and Everything else
 
Management of atrial fibrillation in critically ill patients
Management of atrial fibrillation in critically ill patientsManagement of atrial fibrillation in critically ill patients
Management of atrial fibrillation in critically ill patients
 
Heart failure
Heart failureHeart failure
Heart failure
 
Evaluation and Initial Treatment of Supraventricular Tachycardia
Evaluation and Initial Treatment of Supraventricular TachycardiaEvaluation and Initial Treatment of Supraventricular Tachycardia
Evaluation and Initial Treatment of Supraventricular Tachycardia
 
American Heart Association Emergency Medicine Update Cardiology- EM Residency...
American Heart Association Emergency Medicine Update Cardiology- EM Residency...American Heart Association Emergency Medicine Update Cardiology- EM Residency...
American Heart Association Emergency Medicine Update Cardiology- EM Residency...
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Atrial fibrillation -latest
Atrial fibrillation -latestAtrial fibrillation -latest
Atrial fibrillation -latest
 
ST elevation
ST elevationST elevation
ST elevation
 

Similar to Stieber - Prevention of Postop AF in CT Surgery (2016)

Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020EkaPratiwi69
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal FailureDang Thanh Tuan
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failureguest2379201
 
Emergency medicine research
Emergency medicine researchEmergency medicine research
Emergency medicine researchtbf413
 
ADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENTADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENTdrrajeevsharma7
 
03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgery03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgeryguest2379201
 
03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgery03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac SurgeryDang Thanh Tuan
 
ANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANT
ANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANTANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANT
ANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANTdrvipinKumarGoyal
 
Parathyroidectony IN ESRD 2017
Parathyroidectony IN ESRD  2017Parathyroidectony IN ESRD  2017
Parathyroidectony IN ESRD 2017FarragBahbah
 
early initiation of arni.pptx
early initiation of arni.pptxearly initiation of arni.pptx
early initiation of arni.pptxdkapila2002
 
Principles of diagnosis &amp; management of acute pulmonary
Principles of diagnosis &amp; management of acute pulmonaryPrinciples of diagnosis &amp; management of acute pulmonary
Principles of diagnosis &amp; management of acute pulmonaryVijay Yadav
 
A case of prosthetic mitral valve with
A case of prosthetic mitral valve  withA case of prosthetic mitral valve  with
A case of prosthetic mitral valve withAbhijeet Patil
 
Approach to heart failure cases
Approach to heart failure casesApproach to heart failure cases
Approach to heart failure caseshospital
 
Turp CASE FINAL.pptx
Turp CASE FINAL.pptxTurp CASE FINAL.pptx
Turp CASE FINAL.pptxJeyRaj4
 

Similar to Stieber - Prevention of Postop AF in CT Surgery (2016) (20)

Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020
 
FAT EMBOLISATION , ACS , ABNORMAL RCA CAUSING IWMI
FAT EMBOLISATION , ACS , ABNORMAL RCA  CAUSING IWMIFAT EMBOLISATION , ACS , ABNORMAL RCA  CAUSING IWMI
FAT EMBOLISATION , ACS , ABNORMAL RCA CAUSING IWMI
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
Autopsy conference
Autopsy conferenceAutopsy conference
Autopsy conference
 
Emergency medicine research
Emergency medicine researchEmergency medicine research
Emergency medicine research
 
A case of Compressive Myelopathy
A case of Compressive MyelopathyA case of Compressive Myelopathy
A case of Compressive Myelopathy
 
ADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENTADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENT
 
San jose 2011
San jose 2011San jose 2011
San jose 2011
 
03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgery03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgery
 
03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgery03 Perioperative Renal Failure In Cardiac Surgery
03 Perioperative Renal Failure In Cardiac Surgery
 
ANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANT
ANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANTANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANT
ANESTHESIA CONSIDERATIONS FOR KIDNEY TRANSPLANT
 
Parathyroidectony IN ESRD 2017
Parathyroidectony IN ESRD  2017Parathyroidectony IN ESRD  2017
Parathyroidectony IN ESRD 2017
 
Mortality Meet Presentation by Dr. Saumya Agarwal
Mortality Meet Presentation by Dr. Saumya Agarwal Mortality Meet Presentation by Dr. Saumya Agarwal
Mortality Meet Presentation by Dr. Saumya Agarwal
 
early initiation of arni.pptx
early initiation of arni.pptxearly initiation of arni.pptx
early initiation of arni.pptx
 
Stroke
StrokeStroke
Stroke
 
Principles of diagnosis &amp; management of acute pulmonary
Principles of diagnosis &amp; management of acute pulmonaryPrinciples of diagnosis &amp; management of acute pulmonary
Principles of diagnosis &amp; management of acute pulmonary
 
A case of prosthetic mitral valve with
A case of prosthetic mitral valve  withA case of prosthetic mitral valve  with
A case of prosthetic mitral valve with
 
Approach to heart failure cases
Approach to heart failure casesApproach to heart failure cases
Approach to heart failure cases
 
Turp CASE FINAL.pptx
Turp CASE FINAL.pptxTurp CASE FINAL.pptx
Turp CASE FINAL.pptx
 

Stieber - Prevention of Postop AF in CT Surgery (2016)

  • 1. Prevention of Postoperative Atrial Fibrillation April 7, 2016 NYU Adult-Gerontology Acute Care III Jennifer Stieber
  • 3. HPI This is Martha, 64 y.o. female with history of CAD s/p stents in Oct 2016, HLD, HTN, TR, sleep apnea, insomnia, anxiety, overactive bladder, GERD, lap band removed due to perforation, who presented with cough and fatigue for several weeks, and was treated for RUL pneumonia and abscess as an outpatient with azithromcycin, followed by prednisone and levaquin without improvement. She was referred to thoracic surgery and was admitted for a R thoracotomy and R upper lobe resection.
  • 4. Home meds: lipitor 20mg po daily cymbalta 60mg daily ASA 81 mg daily clopidogrel 75 mg daily Social: No EtOH No tobacco Retired teacher Lives with husband in Brooklyn NKDA
  • 5. Hospital course: 3/9- admitted, IV tygacil started. 3/10 echo done. 3/12 - R upper lobectomy without complications, chest tube placed 3/13 - transferred to POU, hypotension and low UO treated with IVF, albumin, lasix, neo. 3/14 - afib with RVR to 120s, 7.5mg metoprolol, amio load and drip. Neo for BP support. 3/15 - NSR, neo off, transitioned to PO amio, heparin gtt started. lung tissue culture shows moderate Strep intermedius, sputum with H. influenzae 3/16 PICC placed for long term IV abx 3/17 - doing well with PT heparin drip continued 3/18 - doing well with PT. Heparin drip off. 3/19 - chest tube remains with +airleak
  • 6. Physical Exam General appearance: Alert female sitting up in chair, no acute distress Neck: supple, midline Lungs: clear to auscultation bilaterally, R CT to water seal. No crepitus. Heart: S1, S2, regular rate and rhythm Abdomen: soft, nontender, nondistended Extremities: +1 edema to bilateral lower legs, warm and well perfused throughout Pulses: +2 radial pulses, +2 pedal pulses Incision: R thoracotomy incision clean dry intact. No redness, no swelling, no drainage Neurologic: AOx3, responds to questions appropriately, movement and sensation intact throughout. Vital Signs: 110/54 HR 62 97% on room air RR 15 97F
  • 7. Labs: WBC 11 Hgb 8.9 Hct 27.4 Plt 293 Na 130 K 4.2 Cl 99 CO2 25 BUN 26 Cr 0.8 Glu 101 Ca 7.4 Alb 2
  • 8. Imaging Chest CT 03/07/16 Impression: Moderate to large right upper lobe infiltrate with atelectasis containing fluid collection with air-fluid levels, worrisome for abscess.
  • 9. Imaging/tests EKG from 3/14 Ventricular Rate: 105 BPM Atrial Rate: 113 BPM QRS Duration: 146 ms Q-T Interval: 358 ms QTC Calculation(Bezet): 473 ms R Axis: -54 degrees T Axis: 105 degrees Atrial fibrillation with rapid ventricular response Non-specific intra-ventricular conduction delay Nonspecific ST and T wave abnormality Abnormal ECG Echo TTE 03/10/16 CONCLUSION: --There is no left atrial dilatation (LA volume index 24 ml/m²). --There is paradoxical septal motion. Other LV walls are normal. --LV ejection fraction is normal. --The right ventricle has normal wall motion. --The right atrial pressure is normal (0 - 5 mm Hg). There is no pulmonary hypertension. --There is no pericardial effusion. Prominent epicardial fat pad. --No prior study available for comparison. 3/19/16 CXR: Findings / Impression: Status post right thoracotomy for partial right lung resection. Right pleural chest tube remains. Previously described small right apical pneumothorax is no longer discernible. Cardiomediastinal silhouette is unremarkable for portable technique.
  • 10. Assessment This is a 64 year old female with history significant for CAD s/p stents, HLD, HTN, TR, who is post op day #8 s/p R upper lobe resection of a cavitary abscess and pneumonia, course complicated by afib with RVR now on PO amio, rehabilitating well in post op unit.
  • 11. Plan Pulm - s/p RUL lobectomy for cavitary mass - ipratropium neb q4h - albuterol 2.5 mg q4h - Chest PT - incentive spirometry - OOB as tolerated - DC chest tube when air leak resolved Cardiac- CAD s/p stents, HTN, HLD - ASA 81 mg daily - clopidogrel 75 mg daily - lipitor 20mg po daily - amiodarone 400mg PO twice daily - metoprolol 12.5 mg po q12h - heart healthy diet - Maintain K>4 and mag>2 - Daily weights - Trend I/Os Neuro - post op pain, anxiety, insomnia - cymbalta 60mg daily - 5 mg oxycodone q4 hrs PRN for pain
  • 12. Plan Renal - hyponatremia - Trend BUN/Cr - asymptomatic hyponatremia, today Na=130, continue 1000ml daily fluid restriction ID - cavitary lung abscess -s/p PICC - tygacil 50 mg IV q12 hrs - trend WBC - monitor temps q4h - monitor cough and sputum Prophylaxis: - heparin subq 5000 units BID - protonix 40mg daily - Colace/senna
  • 13. Surgery atrial fibrillation Prolongs hospital stay Thromboembolic events Worse long term prognosis $10,000 per patient (Onk and Erkut, 2015)
  • 14. PICO In post-operative cardiothoracic patients, is amiodarone, compared to other therapies, more effective at preventing atrial fibrillation?
  • 15. ● Increased atrial pressure/atrial enlargement ● Metabolic and electrolyte changes ● Myocardial ischemia ● Aging ● Oxidative stress ● Hypertension ● Low EF ● ICU stress ● Pericardial inflammation ● Catecholamine release ● Systemic inflammation ● Local inflammation Hypothesized triggers of atrial fibrillation: ● OR, interaction of all of these factors
  • 16. Study 1: “Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in Reducing Atrial Fibrillation?” 2015 Authors: Onk and Erkut Journal: Medicine Type of study: randomized control trial, nonblind n= 251 Methods: 251 pre-CABG were randomly divided into 2 groups: one given metoprolol 50 mg/day vs amio 200 mg/daydaily 1 week prior to surgery and during post-op period. Followed up 1 month Results: AF in 14 amio patients, AF in 16 metoprolol patients (p=0.612). No significant differences in length of stay, cost of stay (p=0.741) Weaknesses: only 48 hrs of tele, then daily EKG after that. anyone with extensive cardiac history was excluded- valve dysfunction, HF class III, prior stents, etc Strengths: no bradycardia, no heart block, no discontinuation of therapy due to side effects, no statistical differences in vessel disease, the amount of bleeding, inotropic support, duration to extubation, use of IABP, renal dysfunction
  • 17. Study 2: “Role of Atorvastatin Administration in Protection Against Postoperative Atrial Fibrillation Following Conventional CABG” 2011 Authors: Sun et al. Journal: International Heart Journal Type of study: randomized control trial, single blind placebo n= 100 Methods: 49 given atorvastatin 20 mg daily 7 days before surgery, 51 given placebo. The primary endpt was occurrence of AF, CRP was measured pre-op and q24 hrs post op until discharge. Results: Atorvastatin significantly reduced the incidence of postop AF (18% vs 41%, p=0.017). and postop peak CRP level (129 vs 149 p<0.0001.) Significantly better postop afib-free survival in statin group. Pre op atorvastatin tx was independently associated with significant reduction in post op AF (p=0.007). Weaknesses: no race mentioned, hospital stay was 13- 14 days Strengths: ECG for 7 days post op, all operations performed by 1 surgeon. no previous statin use, no hx afib. No sig differences in vessel disease, hx of infarct, HLD, HTN between groups. No GI or
  • 18. Study 3: “Dexamethasone for the prevention of postoperative atrial fibrillation” (DECS trial) 2015 Authors: Osch et al. Journal: International Journal of Cardiology Type of study: randomized control trial, double blind n= 4494 cardiac surgery pts Methods: 2239 received single dose dex, 2255 placebo. Patients were randomized to receive an intravenous injection dexamethasone (1 mg/kg, with a maximum total dose of 100 mg) or placebo, immediately after the induction of anesthesia, but before the initiation of CPB Results: The incidence of any AF in the main study of 4494 patients was 33.1% in the dexamethasone and 35.2% in the placebo group (RR 0.94, 95% CI: 0.87–1.02, p=0.14). In the substudy of 1565 patients (more in depth analysis), the incidence of new onset AF was 33.0% vs. 35.5% (RR 0.93, 95% CI: 0.81–1.07, p=0.31), respectively. Weaknesses: Visceral abdominal obesity is important modulator of postoperative inflammation. Did not collect baseline waist circumference as a possible modulator of the effect of dexamethasone on AF Strengths: high rate of follow up (loss of 4 in exp, loss of 8 in control group). The analysis of the ECGs, patient
  • 19. Study 4: “Ranolazine Enhances the Antiarrhythmic Activity of Amiodarone by Accelerating Conversion of New-Onset Atrial Fibrillation After Cardiac Surgery” 2014 Authors: Simopoulos et al. Journal: Coronary Heart Disease Study year: 2014 Type of study: prospective randomized control trial, single blind n=41, 20 exp, 21 control Methods: enrolled consecutive patients who developed POAF after elective on-pump CABG, randomized to receive either ranolazine 375 mg twice daily orally plus intravenous amiodarone (active group) or intravenous amiodarone alone (control group). Results: Time to conversion, hrs 19.9 vs 37.2 (p<.001) Weaknesses: small sample size, but stat sig. Could be drug independent spontaneous conversion. Strengths: same surgeons and anesthesiologists for each procedure. None of the patients who received ranolazine in addition to amiodarone showed any hemodynamic deterioration or proarrhythmic effects during the entire treatment
  • 20. References: 1. Onk and Erkut. (2015). Is the Preoperative Administration of Amiodarone or Metoprolol More Effective in Reducing Atrial Fibrillation. Medicine. 94(41) 2. Sun Y1, Ji Q, Mei Y, Wang X, Feng J, Cai J, Chi L.(2011). Role of Atorvastatin Administration in Protection Against Postoperative Atrial Fibrillation Following Conventional CABG. International Heart Journal 52(1):7-11. 3. Osch, Dieleman, van Dijk, Jacob, Luin, Doevendans, Nathoe. (2015). Dexamethasone for the prevention of postoperative atrial fibrillation. International Journal of Cardiology 182:431-437. 4. Simopoulos, V, Tagarakis G, Daskalopoulou S, Chryssagis, K, Skoularingis, I, Molyvdas, P, Tisilimingas, N, Aidonidis, I. (2014). Ranolazine Enhances the Antiarrhythmic Activity of Amiodarone by Accelerating Conversion of New-Onset Atrial Fibrillation After Cardiac Surgery. Coronary Heart Disease 65(4) 294-297.

Editor's Notes

  1. Amiodarone is categorized as a class III antiarrhythmic agent, and prolongs phase 3 of the cardiac action potential, the repolarization phase where there is normally decreased calcium permeability and increased potassium permeability.
  2. From study: “statins, independent of their cholesterol lowering property, are reported to reduct the risk of atrial fibrillation through their pleiotropic effects (Pleiotropy occurs when one gene influences two or more seemingly unrelated phenotypic traits), such as anti inflammatory and antioxidant properties, modification of extracellular matrix modeling, and indirect antiarrhythmic effects by autonomic modulation, or direct antiarrhythmic effects through stabilization of transmembrane ion channel properties. CRP is used to measure systemic inflammation.
  3. Substudy studied use of beta blocker, corticosteroids, amio
  4. Ranexa approved in 2006. Atrial selective. prolonging refractoriness of atrial muscle .ranolazine inhibits the late inward sodium current in heart muscle.[5] Inhibiting that current leads to reductions in elevated intracellular calcium levels. This in turn leads to reduced tension in the heart wall, leading to reduced oxygen requirements for the muscle. Indicated for angina. Study conclusion: synergistic electrophysiologic effect of ranolazine in combination with amiodarone without causing proarrhythmia. However, larger prospective trials are needed to confirm these findings and to identify the underlying mechanisms that explain the antiarrhythmic potency of ranolazine plus amiodarone combination therapy for the conversion of POAF.